Article Text

other Versions

PDF
Original research
Trajectories of prostate-specific antigen after treatment for prostate cancer
  1. Ziyue Wu1,
  2. Mihaela Aslan2,3,
  3. Haiqun Lin4,
  4. John Ko2,
  5. Krishnan Radhakrishnan2,
  6. Carolyn K Wells3,
  7. Edward Uchio5,
  8. John Concato2,3
  1. 1Biostatistics, Yale University School of Public Health, New Haven, Connecticut, USA
  2. 2Department of Veterans Affairs Connecticut Healthcare System, Clinical Epidemiology Research Center, Veterans Affairs Medical Center (VAMC), West Haven, Connecticut, USA
  3. 3Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA
  4. 4Department of Biostatistics, Yale University School of Public Health, Decatur, Georgia, USA
  5. 5Department of Urology, University of California, Irvine, California, USA
  1. Correspondence to Dr John Concato, Department of Veterans Affairs Connecticut Healthcare System, Clinical Epidemiology Research Center, Veterans Affairs Medical Center (VAMC), West Haven, CT 06516, USA; john.concato{at}yale.edu

Abstract

Prostate-specific antigen (PSA) measurements after primary treatment reflect residual tumor burden among men with prostate cancer. Using a mixture model analysis, we identified distinct trajectories of post-treatment PSA measurements and evaluated their associations with prostate cancer mortality. The study sample included 623 US Veterans treated for prostate cancer with curative intent during 1991–1995; 225 men received surgery and 398 men received radiation therapy. Post-treatment PSA measurements over a 2-year period for each patient were evaluated in latent class mixture models using the SAS TRAJ procedure, and groups of men with distinct trajectories of PSA were identified. These groups were then assessed for associations with 10-year prostate cancer mortality using proportional hazards analysis. Analyses identified three distinct groups—representing patterns of both initial values and changes in PSA over time—after surgery (n=172/31/14) and radiation therapy (n=253/103/22). Men in groups with patterns of higher (compared with the group with lowest) PSA values tended to have worse survival experience: HRs for prostate cancer mortality were 3.45 (P=0.18) and 22.7 (P<0.001) for surgery, and 2.70 (P=0.005) and 18.1 (P<0.001) for radiation therapy. The results indicate that PSA measurements after surgery or radiation therapy with curative intent include groups of men with a diverse spectrum of prognosis for prostate cancer mortality. Although contemporary PSA levels are lower than those observed in the study sample, the corresponding trajectory patterns may become evident shortly after the time of diagnosis and treatment.

  • cancer
  • prognosis
  • diagnostic tests
  • routine

Statistics from Altmetric.com

Footnotes

  • Contributors EU and JC developed the study design and drafted the manuscript. ZW, MA and HL conducted the analyses. KR and CKW provided critical feedback. All authors participated in revisions of the manuscript.

  • Disclaimer The content of this manuscript is the responsibility of the authors alone and does not necessarily reflect the views or policies of the Department of Veterans Affairs or the US Government.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Author note ZW is now with Emory University in Atlanta, Georgia, USA.

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.